Trial · NCT02251275
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Tolvaptan) | Participants with TEAEs | 473 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Placebo) | Participants with TEAEs | 531 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-08-271: Tolvaptan) | Participants with TEAEs | 640 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Tolvaptan) | Participants with TEAEs | 6 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Placebo) | Participants with TEAEs | 3 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Tolvaptan) | Participants with serious TEAEs | 87 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Placebo) | Participants with serious TEAEs | 96 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-08-271: Tolvaptan) | Participants with serious TEAEs | 103 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Tolvaptan) | Participants with serious TEAEs | 1 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Placebo) | Participants with serious TEAEs | 2 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Tolvaptan) | Participants with severe TEAEs | 74 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Placebo) | Participants with severe TEAEs | 78 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-08-271: Tolvaptan) | Participants with severe TEAEs | 83 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Tolvaptan) | Participants with severe TEAEs | 2 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Placebo) | Participants with severe TEAEs | 1 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Tolvaptan) | Discontinued due to TEAEs | 33 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-13-210: Placebo) | Discontinued due to TEAEs | 65 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From 156-08-271: Tolvaptan) | Discontinued due to TEAEs | 38 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Tolvaptan) | Discontinued due to TEAEs | 0 | participants | |
| Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | Tolvaptan (From Other: Placebo) | Discontinued due to TEAEs | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02251275/results